MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV) in a report published on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Price Performance

Shares of MNOV opened at $1.53 on Thursday. MediciNova has a 12 month low of $1.12 and a 12 month high of $2.16. The stock’s 50 day moving average is $1.81 and its two-hundred day moving average is $1.50.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts forecast that MediciNova will post -0.23 earnings per share for the current fiscal year.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.